Low-dose IL-2 treatment has been shown to expand the Treg population in patients with SLE (33, 34) and is used in clinical trials for treatment of autoimmune diseases, including SLE, rheumatoid arthritis, and multiple sclerosis (7). This evidence concerns the gene IL2 and systemic lupus erythematosus.